

Acetylsalicylic Acid in Migraine with Aura Prevention - a Retrospective Study

MIHAELA-BIANCA ANOAIKA¹, P.G. ANOAIKA², FLORICA POPESCU³

¹Headache Centre, Neurology II, Department of Neurosciences, University of Turin, Molinette Hospital, Turin, Italy

²University of Medicine and Pharmacy of Craiova, Department of Biophysics

³University of Medicine and Pharmacy of Craiova, Department of Pharmacology

ABSTRACT: In a retrospective study we evaluated the efficacy and tolerability of Acetylsalicylic Acid (ASA), an antiplatelet drug, in the prophylactic treatment of migraine with aura (MA). We reviewed the charts of 203 patients suffering from MA according to the ICHD II criteria, attending to Turin University Headache Centre. 95 subjects (46.8%) were treated with ASA at low dose, 108 (53.2%) with other prophylactic therapies normally used for migraine for a period that ranged from at least 4 months to 194 months. Eighty-four patients (88.4%) treated with ASA referred positive results, while only 64 patients (59.3%) who underwent other prophylactic treatments did ($p < 0.001$). The attacks' frequency of patients treated with ASA decreased significantly from 3.83 ± 1.57 pre-treatment to 1.38 ± 0.87 after treatment ($p < 0.001$). Aura duration was markedly reduced from 36.21 ± 19.80 pre-treatment to 22.0 ± 15.5 after treatment ($p < 0.001$). ASA was well-tolerated. ASA is a safe drug with minor possible side effects that can be routinely used when prophylactic treatment of MA is required.

KEYWORDS: Aura, Migraine, Acetylsalicylic Acid, Prophylaxis

Introduction

Migraine with aura (MA) is a primary headache disorder that affects about 30% of migraine sufferers. The International Headache Society's (IHS) diagnostic criteria for MA [1] provide a clinical description of the aura, the disorder's most distinctive feature: aura consists of transient, unilateral or bilateral visual, sensory or motor symptoms considered to arise from a recurrent reversible, idiopathic dysfunction of the cortex or brainstem.

MA in the majority of cases is a relatively easy-to-diagnose form of headache, but when confronted with it, the real challenge is to select the most effective treatment.

The treatment of MA symptoms often represents a major clinical problem for headache specialists. MA usually is characterized by low frequency attacks: three or four attack/year, and does not need a prophylactic therapy [2]. However, in some patients the frequency of the auras attacks is higher, one or more in a month and, in others, the number of auras may increase from few to many attacks in a month or week. In such cases, prophylaxis of MA is justified after organic causes have been excluded.

Although vascular changes are no longer considered the primary cause of migraine headache, and the genesis of aura could be mainly linked to neuronal changes [3] due to the cortical spreading depression (SD) and changes in ion homeostasis, especially that of glutamate

[4,5], resulting in cortical hypoperfusion through neuronal depolarisation in the cerebral cortex, platelets could probably still play an important role in MA pathogenesis. Platelets of migraine sufferers, in fact, present several functional anomalies regarding the content of granules and their secretion, adequately stimulated [6]. In particular, in comparison to healthy control subjects, higher levels of excitatory amino acids, such as glutamic and aspartic acids, are stored in dense bodies. During migraine attacks, platelet activation occurs with release of dense bodies content in cerebral circulation [7]. Release of glutamate may be essential in the initiation and propagation of spreading cortical depression and aura which some believe is central to the genesis of migraine attacks [8]. Based on these considerations, theoretically any prophylactic treatment with anti-aggregation agents may prevent the MA by inhibiting platelet dense bodies release.

The aim of this study is to evaluate if Acetylsalicylic Acid, an antiplatelet drug that irreversibly inhibits platelet cyclooxygenase (COX)-1, the key step in the production of TXA₂ from arachidonic acid (AA), may be useful in the prophylactic treatment of MA. ASA is known to be a potent anti-platelet aggregation drug [9-12]. Such activity has been shown in vitro to be primarily due to an irreversible block of cyclo-oxygenase activity [11-14] the enzyme which catalyzes the transformation of arachidonic acid into the cyclic endoperoxides PGG₂ and PGH₂,

intermediate products, in the production of the "aggregatory" thromboxane A₂ [15]. The irreversibility of the aspirin effect is consequent on the anuclear platelet incapability of enzyme re-synthesis [16]. On the other hand, blockade by aspirin of endothelial cyclo-oxygenase activity results in lower production of prostacyclin, an "anti-aggregatory" agent [17]. This "aspirin therapy dilemma" may be bypassed by using low doses of aspirin [18-21]. Low doses of aspirin have been reported to inhibit in vitro only platelet cyclo-oxygenase activity and to result in reduced formation of salicylate, which is known to disturb aspirin antiaggregatory effects [22]. It is to be stressed that data emphasize lack of aspirin efficacy in women following administration of high doses of aspirin [23].

In the past some studies used ASA at low dose in the prophylaxis of MA with controversial results [24-26].

Methods

We reviewed the charts of 203 (139 females and 64 males, age range 8-87 yrs, mean 34.2±12.74 STD) patients suffering from MA according to the ICHD II criteria, attending to Turin University Headache Centre from 1988 to 2007. 95 subjects (46.8%) were treated with ASA at low dose, 108 (53.2%) with other prophylactic therapies normally used for migraine for a period that ranged from at least 4 months to 194 months.

Patients taking ASA began with a dosage of 300 mg/day for minimum 4 months, and then reduced the dosage to 200 and 100 mg/day.

The primary objective of this study was to evaluate the efficacy and tolerability of Acetylsalicylic Acid for migraine with aura prophylaxis compared with other prophylactic therapies normally used for migraine in a real world clinical setting.

Headache frequency, duration, intensity, disability, accompanying symptoms, duration and intensity of the aura were evaluated before beginning the treatment and after the end of it. Depending on these parameters, it has been given a positive or negative judgment as regarding the response to treatments.

There were analysed the attacks' frequency and the aura duration in the group of patients treated with ASA.

There were analyzed also the adverse events in the two groups.

Statistical Analysis: Continuous data were shown as mean ± SD and categorical data as

counts and percentages. Normally distributed variables were compared by Student's *t* test, whereas categoric variables were compared with the use of the χ^2 test with Fisher's exact test or Yates' continuity correction when necessary. The differences pre-post ASA treatment were evaluated by using the Student's *t* test for paired samples. Data were collected and reviewed in Microsoft Excel and statistical analysis was performed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA). All 2-tailed $P < 0.05$ were considered statistically significant.

Results

Eighty-four patients (88.4%) treated with ASA referred positive results, while only 64 patients (59.3%) who underwent other prophylactic treatments did ($p < 0.001$).

The attacks' frequency of patients treated with ASA decreased significantly from 3.83±1.57 pre-treatment to 1.38±0.87 after treatment ($p < 0.001$). Aura duration was markedly reduced from 36.21±19.80 pre-treatment to 22.0±15.5 after-treatment ($p < 0.001$). In 7 out of 95 (7.3%) MA totally disappeared. Only 11 out of 95 (11.5%) patients were completely unresponsive to treatment.

ASA was well-tolerated. Mild gastralgia in 17 out of 95 patients (17.9%) treated with ASA was the unique adverse event reported.

Conclusions and discussion

On the basis of the data of this retrospective analysis ASA appeared more effective in the prophylactic treatment for MA than other prophylactic therapies normally used for migraine. ASA significantly reduces attacks frequency and length of auras.

SD is considered the pathophysiological mechanism that underlies the MA. Glutamate play a critical role in initiating and propagating SD. It is released in cerebral circulation from the dense bodies of the platelets, during migraine attacks, when platelet activation occurs. Thus, any drug that determine the inhibition of platelet activation and of the secretion of excitatory amino acids from dense granules in the cerebral circulation can be an useful strategy in the treatment of MA.

Our study clearly suggests that it is possible to prevent MA attacks with agents that interfere with the pathophysiological chain of events that may trigger the aura, such as the antiplatelet agents, ASA in this specific case.

So, we conclude that ASA is a safe drug with minor possible side effects that can be routinely

used when prophylactic treatment of MA is required. Nevertheless, this is a retrospective study and should be interpreted with caution and in any case confirmed by prospective studies.

References

1. Headache Classification Committee of the International Headache Society; Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia* 1988; 8 (suppl 7): 1-96.
2. Cologno D, Torelli P, Cademartiri C, Manzoni GC. A prospective study of migraine with aura attacks in a headache clinic population, *Cephalalgia* 2000; 20 (10): 925-30.
3. Lauritzen M. Pathophysiology of the migraine aura, *Brain* 1994; 117: 199-210.
4. Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura a pilot study, *Cephalalgia* 1999; 19: 58-63.
5. D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study, *Cephalalgia* 1999; 19: 64-66.
6. Cananzi AR, D'Andrea G, Perini F, Welch KM. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura, *Cephalalgia* 1995; 15: 13235.
7. D'Andrea G, Toldo M, Cortellazzo S, Milone FF. Platelet activity in migraine, *Headache* 1982; 22: 207-12.
8. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura, *Cephalalgia* 1997; 17: 101-02.
9. Evans G, Packham MA, Nishizawa EE, Mustard JF, Murphy EA. The effect of ASA on platelet function, *J Exp Med* 1968; 128 (40): 877-94.
10. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man, *J Clin Invest* 1968; 47 (41): 2169-80.
11. O'Brien JR. Effects of salicylates on human platelets 1968, *Lancet* 291(7536): 779-83.
12. Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion, *Proc Soc Exp Biol Med* 1968; 43(127): 547-51.
13. Baezinger NL, Dillender MJ, Majerus PW. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin, *Biochem Biophys Res Commun* 1977;78: 294-301
14. Moncada S, Vane JR. Arachidonic acid metabolites and the inter-actions between platelets and blood-vessel walls, *N Engl J Med* 1979; 300: 1142-47.
15. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides thromboxane A2 and prostacyclin, *Pharmacol Rev* 1979; 30: 293-331.
16. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin, *Proc Natl Acad Sci USA* 1975; 72: 3073-76.
17. Hanley SP, Bevan J, Cockbill SR, Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis, *Lancet* 1981; 317 (8227): 969-971.
18. De Gaetano G, Cerletti C, Berteli V. Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link, *Lancet* 1982; 320 (8305): 974-77.
19. Patrignani P, Filabizzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects, *J Clin Invest* 1982; 69: 1366-72.
20. Masotti G, Galanti G, Poggese L, Abbate R, Neri Serneri GG. Differential inhibition of prostacyclin production and platelet aggregation by aspirin, *Lancet* 1979; 314 (8154): 1213-16.
21. Pareti FI, D'Angelo A, Mannucci PM, Smith JB. Platelets and the vessel wall: how much aspirin. *Lancet* 1980; 315 (8154): 371-72.
22. Merino J, Livio M, Raitar G, De Gaetano G. Salicylate reverses "in vivo" aspirin inhibition of rat platelet and vascular prostaglandin generation, *Biochem Pharmacol* 1980; 29: 1093-95.
23. Coppe D, Wessinger SJ, Ransil BJ, Harris W, Salzman E. Sex differences in the platelet response to aspirin, *Thromb Res* 1981; 23: 1-21.
24. Peto R. Treating migraine, *BMJ* 1989; 299: 517-17
25. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis, *JAMA* 1990; 264: 1711-13
26. Bensenor IM, Cook NR, Lee IM, Chown MJ, Hennekens CH, Buring JE. Low-dose aspirin for migraine prophylaxis in women, *Cephalalgia* 2001; 21:175-83

Corresponding author: Mihaela Bianca Anoaica, Via Amendola 19, Cameriano, Novara, Italy;
e-mail: dott.bianca@libero.it